Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Kast

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Journal of Clinical Pharmacy and Therapeutics|November 9, 2010
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drugR E Kast
Archiv Fur Geschwulstforschung|January 1, 1977
Interpretation of the common tumour antigen (CTA)--an antigen present on all human malignant tumour cells and suspected of mediating malignant growth of cellsR E Kast
Radiobiologia, Radiotherapia|January 1, 1977
Radiodiagnostic and radiotherapeutic implications of the recent discovery of a common malignant tumour antigen, CTA, absolutely unique to cancer cellsR E Kast
Leukemia Research|June 21, 2005
Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities--the role of bupropionR E Kast
Central European Neurosurgery|February 4, 2010
Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rheumatoid arthritis drugR E Kast
Oncology Research|June 24, 2009
Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancerR E Kast
Anesthesia Progress|October 29, 2005
Tiagabine may reduce bruxism and associated temporomandibular joint painR E Kast
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 7, 2000
Non-steroidal anti-inflammatory drugs might also be pro-inflammatory by increasing tumor necrosis factorR E Kast
International Journal of Immunopharmacology|November 25, 2000
Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMPR E Kast
Medical Hypotheses|January 1, 1980
Cancer diagnostic test of Field and Caspary: Part II. A review and interpretation of the collected dataR E Kast
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Journal of Clinical Pharmacy and Therapeutics|November 9, 2010
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drugR E Kast
Archiv Fur Geschwulstforschung|January 1, 1977
Interpretation of the common tumour antigen (CTA)--an antigen present on all human malignant tumour cells and suspected of mediating malignant growth of cellsR E Kast
Radiobiologia, Radiotherapia|January 1, 1977
Radiodiagnostic and radiotherapeutic implications of the recent discovery of a common malignant tumour antigen, CTA, absolutely unique to cancer cellsR E Kast
Leukemia Research|June 21, 2005
Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities--the role of bupropionR E Kast
Central European Neurosurgery|February 4, 2010
Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rheumatoid arthritis drugR E Kast
Oncology Research|June 24, 2009
Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancerR E Kast
Anesthesia Progress|October 29, 2005
Tiagabine may reduce bruxism and associated temporomandibular joint painR E Kast
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 7, 2000
Non-steroidal anti-inflammatory drugs might also be pro-inflammatory by increasing tumor necrosis factorR E Kast
International Journal of Immunopharmacology|November 25, 2000
Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMPR E Kast
Medical Hypotheses|January 1, 1980
Cancer diagnostic test of Field and Caspary: Part II. A review and interpretation of the collected dataR E Kast
Pageof 6